Prof Banu Arun speaks to ecancer as part of BGICC 2023 about post neoadjuvant management in BRCA mutant breast cancer patients.
She summarises the treatment options for patients with germline BRCA mutations who received neoadjuvant chemotherapy.
Some of these treatment options include pembrolizumab and olaparib.